Treatment-resistant depression (TRD) is generally defined as major depressive disorder that has failed to respond adequately to two or more antidepressant trials of adequate dose and duration. Per the major 2023 World Psychiatry review by McIntyre and colleagues, approximately 30% of patients with major depression meet criteria for TRD.
This isn’t a fringe situation — it’s a substantial portion of depressed patients. And it’s a situation where specialty psychiatric care matters most, because effective treatment requires sequential, evidence-based strategies beyond standard first-line approaches.
What “Treatment-Resistant” Actually Means
The most widely used definition (Thase-Rush staging) requires:
- Failure to respond to two or more antidepressant trials of adequate dose and duration
- Adequate dose typically means therapeutic dose range
- Adequate duration typically means 6-8 weeks at therapeutic dose
- Failure means less than 50% symptom reduction or failure to achieve remission
Important caveat: many cases labeled “treatment-resistant” actually haven’t received adequate trials. Common issues include doses too low, duration too short, poor adherence, or untreated contributing factors (sleep apnea, thyroid disease, substance use). Specialty evaluation often identifies these issues before declaring true treatment resistance.
STAR*D Trial Findings
The landmark STAR*D trial provided critical data on sequential treatment:
- Level 1 (initial SSRI): approximately 33% remission
- Level 2 (switch or augment after Level 1 failure): approximately 31% of remaining patients
- Level 3: approximately 14% additional remission
- Level 4: approximately 13% additional remission
Theoretical cumulative remission across 4 sequential treatment steps was 67% in the original analysis, though subsequent methodological reanalyses suggest 35-50% with more conservative methodology. The implication remains clear: sequential treatment substantially improves outcomes vs. giving up after one or two failed trials.
Causes of Apparent Treatment Resistance
Before declaring true TRD, evaluation should consider:
Inadequate treatment
- Subtherapeutic doses
- Inadequate duration
- Poor adherence
- Drug interactions reducing efficacy
Missed diagnoses
- Bipolar disorder presenting as depression (one of the most common missed diagnoses)
- Subtle psychotic features
- OCD or anxiety coexistence
- Personality features affecting treatment
- PTSD contribution
Medical contributors
- Hypothyroidism or subclinical thyroid dysfunction
- Vitamin D deficiency
- B12 deficiency
- Sleep apnea (often unrecognized)
- Chronic pain
- Anemia
- Cardiovascular disease
- Diabetes
Substance contributions
- Alcohol use (often understated by patients)
- Cannabis use
- Other substance use
- Medications with depression as side effect (interferon, some hormones, others)
Evidence-Based TRD Strategies
Switching strategies
- Switch within class (one SSRI to another)
- Switch between classes (SSRI to SNRI to bupropion)
- Switch to vortioxetine (different mechanism)
- Switch to mirtazapine
- Switch to MAOI for highly resistant cases
Augmentation strategies
Per APA practice guidelines and substantial evidence base:
- Lithium augmentation — Extensive evidence; particularly for unipolar depression
- Atypical antipsychotic augmentation — Aripiprazole, brexpiprazole, cariprazine, quetiapine XR all have FDA approval for adjunctive treatment of MDD
- T3 (liothyronine) augmentation — Evidence base; STAR*D Level 3 data
- Combining antidepressants — Adding bupropion or mirtazapine to SSRI/SNRI
Advanced treatments
- Esketamine (Spravato) — FDA-approved 2019 for TRD; rapid antidepressant effects via NMDA receptor modulation; administered in healthcare settings with monitoring; per recent ESCAPE-TRD trial, demonstrated superiority over quetiapine XR at week 8
- IV ketamine — Off-label use; substantial evidence base for rapid antidepressant effects
- Repetitive Transcranial Magnetic Stimulation (TMS) — FDA-approved; non-invasive brain stimulation
- Theta burst stimulation (TBS) — Newer TMS variant; FDA approved
- Electroconvulsive Therapy (ECT) — Highly effective for severe and treatment-resistant cases; remains gold-standard for severe TRD per APA guidelines
- Vagus Nerve Stimulation (VNS) — FDA-approved for TRD though less commonly used
Psychotherapy in TRD
Even with biological treatments, evidence-based psychotherapy (CBT, IPT, behavioral activation, MBCT) typically improves outcomes. Combination of medication and therapy often produces synergistic effects in TRD.
Source: STAR*D trial; McIntyre et al. (2023) World Psychiatry review.
Premature labeling
Many patients labeled “treatment-resistant” haven’t received adequate trials of appropriate medications at therapeutic doses — leading to unwarranted pessimism.
Comprehensive evaluation
Dr. Farkas systematically evaluates apparent TRD — addressing inadequate prior treatment, missed diagnoses, medical contributors, and substance factors.
Real treatment options
Most patients with true TRD have multiple evidence-based treatment options remaining — substantial remission is achievable for the majority.
Common Questions About Treatment-Resistant Depression
How do I know if my depression is truly treatment-resistant?
True TRD requires confirmed adequate trials (therapeutic doses, 6-8 weeks each, adequate adherence). Specialty evaluation can clarify whether trials have been adequate and whether other factors contribute.
What’s the most effective TRD treatment?
No single “most effective” treatment exists — different patients respond to different approaches. Esketamine, TMS, and ECT all have strong evidence. Augmentation strategies (lithium, atypical antipsychotics) work for many patients. Treatment selection should be individualized.
Should I try ketamine or esketamine?
For appropriate TRD candidates, FDA-approved esketamine (Spravato) has substantial evidence. IV ketamine is more widely available but off-label. Both require careful evaluation and monitoring. See our related articles on major depression and recurrent depression.
Is ECT really safe?
Modern ECT is substantially safer than its historical reputation suggests. Per APA practice guidelines, ECT is highly effective for severe TRD and remains an important option. Cognitive side effects are common but typically resolve. Risk-benefit analysis often favors ECT for severe cases.